| Drug General Information |
| Drug ID |
D0QQ1J
|
| Former ID |
DNC011355
|
| Drug Name |
BITHIONOL
|
| Drug Type |
Small molecular drug
|
| Indication |
Trematode infection [ICD10:B66.9]
|
Withdrawn from market |
[1],
[2]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C12H6Cl4O2S
|
| InChI |
InChI=1S/C12H6Cl4O2S/c13-5-1-7(15)11(17)9(3-5)19-10-4-6(14)2-8(16)12(10)18/h1-4,17-18H
|
| InChIKey |
JFIOVJDNOJYLKP-UHFFFAOYSA-N
|
| CAS Number |
CAS 97-18-7
|
| PubChem Compound ID |
|
| PubChem Substance ID |
10168, 75233, 100332, 603045, 855531, 4908298, 7847867, 8149224, 8151613, 10538866, 11335814, 11361053, 11362922, 11365484, 11368046, 11371518, 11373833, 11376208, 11462025, 11483862, 11487929, 11490135, 11492072, 11493902, 11533319, 12054579, 15472383, 17389712, 24900609, 26751444, 29221571, 46508019, 47365181, 47440246, 47662279, 47959736, 48184990, 48414531, 48422207, 48424455, 49856124, 50100878, 56313666, 56404185, 56459051, 57321306, 57654715, 74382877, 78335568, 87576694
|
| SuperDrug ATC ID |
D10AB01; P02BX01
|
| Target and Pathway |
| Target(s) |
Estrogen receptor |
Target Info |
Inhibitor |
[3]
|
|---|
| Calpain |
Target Info |
Inhibitor |
[3]
|
| Estrogen receptor beta |
Target Info |
Inhibitor |
[3]
|
| Induced myeloid leukemia cell differentiation protein Mcl-1 |
Target Info |
Inhibitor |
[3]
|
|
KEGG Pathway
|
Estrogen signaling pathway
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Endocrine and other factor-regulated calcium reabsorption
|
|
Proteoglycans in cancerhsa04141:Protein processing in endoplasmic reticulum
|
|
Apoptosis
|
|
Alzheimer's diseasehsa04915:Estrogen signaling pathway
|
|
Prolactin signaling pathwayhsa04151:PI3K-Akt signaling pathway
|
|
MicroRNAs in cancer
|
|
NetPath Pathway
|
FSH Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
RANKL Signaling PathwayNetPath_11:TCR Signaling Pathway
|
|
PANTHER Pathway
|
Apoptosis signaling pathway
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
|
Signaling events mediated by HDAC Class II
|
|
Plasma membrane estrogen receptor signaling
|
|
LKB1 signaling events
|
|
Regulation of Telomerase
|
|
ATF-2 transcription factor network
|
|
AP-1 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Validated nuclear estrogen receptor alpha network
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
FOXA1 transcription factor networker_nongenomic_pathway:Plasma membrane estrogen receptor signaling
|
|
Validated nuclear estrogen receptor beta network
|
|
Validated nuclear estrogen receptor alpha networke2f_pathway:E2F transcription factor network
|
|
Direct p53 effectors
|
|
IL6-mediated signaling events
|
|
HIF-1-alpha transcription factor network
|
|
Reactome
|
Nuclear signaling by ERBB4
|
|
Nuclear Receptor transcription pathwayR-HSA-1474228:Degradation of the extracellular matrixR-HSA-383280:Nuclear Receptor transcription pathway
|
|
WikiPathways
|
Estrogen signaling pathway
|
|
Nuclear Receptors Meta-Pathway
|
|
Estrogen Receptor Pathway
|
|
Signaling by ERBB4
|
|
JAK/STAT
|
|
Integrated Pancreatic Cancer Pathway
|
|
Leptin signaling pathway
|
|
miR-targeted genes in muscle cell - TarBase
|
|
Integrated Breast Cancer Pathway
|
|
Nuclear ReceptorsWP306:Focal Adhesion
|
|
Alzheimers Disease
|
|
Integrin-mediated Cell AdhesionWP706:SIDS Susceptibility Pathways
|
|
Ovarian Infertility Genes
|
|
Nuclear ReceptorsWP254:Apoptosis
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in leukocytes - TarBase
|
|
Apoptosis Modulation and Signaling
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2338). |
|---|
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
|---|
| REF 3 | Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. Epub 2010 Oct 21.In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). |
|---|
